Cargando…

High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells

Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small molecules that selectively inhibit the growth of CALR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Ruochen, Kutzner, Leon, Koren, Anna, Runggatscher, Kathrin, Májek, Peter, Müller, André C., Schuster, Michael, Bock, Christoph, Loizou, Joanna I., Kubicek, Stefan, Kralovics, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325683/ https://www.ncbi.nlm.nih.gov/pubmed/34333533 http://dx.doi.org/10.1038/s41408-021-00531-2

Ejemplares similares

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Allelic imbalance in CALR somatic mutagenesis
por: Harutyunyan, A S, et al.
Publicado: (2015)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

Thrombopoietin receptor is required for the oncogenic function of CALR mutants
por: Nivarthi, H, et al.
Publicado: (2016)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy
por: Ahmed, Salman, et al.
Publicado: (2022)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
por: Ma, Hanhui, et al.
Publicado: (2013)

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors()
por: Job, Albert, et al.
Publicado: (2018)

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition
por: Sundararajan, Vignesh, et al.
Publicado: (2022)

CTP sensing and Mec1(ATR)-Rad53(CHK1/CHK2) mediate a two-layered response to inhibition of glutamine metabolism
por: Ajazi, Arta, et al.
Publicado: (2022)

Multiple ATR-Chk1 Pathway Proteins Preferentially Associate with Checkpoint-Inducing DNA Substrates
por: Yilmaz, Seçil, et al.
Publicado: (2011)

Correction for The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
Publicado: (2013)

Critical role of SMG7 in activation of the ATR-CHK1 axis in response to genotoxic stress
por: Ho, Kathleen, et al.
Publicado: (2021)

PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors
por: Göder, Anja, et al.
Publicado: (2023)

7-Ketocholesterol induces ATM/ATR, Chk1/Chk2, PI3K/Akt signalings, cytotoxicity and IL-8 production in endothelial cells
por: Chang, Mei-Chi, et al.
Publicado: (2016)

Tim–Tipin dysfunction creates an indispensible reliance on the ATR–Chk1 pathway for continued DNA synthesis
por: Smith, Kevin D., et al.
Publicado: (2009)

ATR and a Chk1-Aurora B pathway coordinate postmitotic genome surveillance with cytokinetic abscission
por: Mackay, Douglas R., et al.
Publicado: (2015)

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
por: Chen, Sansan, et al.
Publicado: (2016)

Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation
por: Shen, Tao, et al.
Publicado: (2018)

An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells
por: Mordasini, Vanessa, et al.
Publicado: (2016)

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
por: Gralewska, Patrycja, et al.
Publicado: (2020)

The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion
por: Dembitz, Vilma, et al.
Publicado: (2019)

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
por: Nie, Sipei, et al.
Publicado: (2021)

ASPM promotes ATR-CHK1 activation and stabilizes stalled replication forks in response to replication stress
por: Wu, Xingxuan, et al.
Publicado: (2022)

APE1 assembles biomolecular condensates to promote the ATR–Chk1 DNA damage response in nucleolus
por: Li, Jia, et al.
Publicado: (2022)

The MRN complex maintains the biliary-derived hepatocytes in liver regeneration through ATR-Chk1 pathway
por: Song, Jingmei, et al.
Publicado: (2023)

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis
por: Shide, Kotaro, et al.
Publicado: (2019)

Mangrove dolabrane‐type of diterpenes tagalsins suppresses tumor growth via ROS‐mediated apoptosis and ATM/ATR–Chk1/Chk2‐regulated cell cycle arrest
por: Neumann, Jennifer, et al.
Publicado: (2015)

ATR and Chk1 Suppress a Caspase-3–Dependent Apoptotic Response Following DNA Replication Stress
por: Myers, Katie, et al.
Publicado: (2009)

Direct requirement for Xmus101 in ATR-mediated phosphorylation of Claspin bound Chk1 during checkpoint signaling
por: Yan, Shan, et al.
Publicado: (2006)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
por: Li, Ching-Chia, et al.
Publicado: (2015)

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer
por: Doerr, Fabian, et al.
Publicado: (2017)

Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation
por: Luo, Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1v2lrbk3b9nii9g038iuiijdae